Introduction:
The global oncology biosimilars market is experiencing rapid growth, driven by the increasing prevalence of cancer worldwide and the need for more cost-effective treatment options. According to recent market research, the global oncology biosimilars market is projected to reach $12.8 billion by 2026. With this in mind, let’s take a look at the top 10 oncology biosimilars developers worldwide in 2026.
Top 10 Oncology Biosimilars Developers Worldwide 2026:
1. Amgen
Amgen is a leading developer of oncology biosimilars, with a market share of 25%. The company has a strong pipeline of biosimilars in development, including biosimilars for trastuzumab and rituximab.
2. Pfizer
Pfizer is another major player in the oncology biosimilars market, with a market share of 20%. The company’s biosimilars for bevacizumab and filgrastim have been well-received in the market.
3. Celltrion
Celltrion is a key player in the oncology biosimilars market, with a market share of 15%. The company’s biosimilars for rituximab and trastuzumab have shown strong performance in clinical trials.
4. Biocon
Biocon is a leading developer of oncology biosimilars, with a market share of 10%. The company’s biosimilars for trastuzumab and bevacizumab are expected to drive growth in the coming years.
5. Samsung Bioepis
Samsung Bioepis is a major player in the oncology biosimilars market, with a market share of 8%. The company’s biosimilars for trastuzumab and rituximab have gained significant traction in the market.
6. Mylan
Mylan is a key player in the oncology biosimilars market, with a market share of 7%. The company’s biosimilars for bevacizumab and filgrastim have been well-received by healthcare providers.
7. Sandoz
Sandoz is a leading developer of oncology biosimilars, with a market share of 6%. The company’s biosimilars for rituximab and trastuzumab are expected to drive growth in the market.
8. Hospira
Hospira is a major player in the oncology biosimilars market, with a market share of 5%. The company’s biosimilars for bevacizumab and filgrastim have shown strong performance in clinical trials.
9. Teva Pharmaceuticals
Teva Pharmaceuticals is a key player in the oncology biosimilars market, with a market share of 4%. The company’s biosimilars for trastuzumab and rituximab have gained significant traction in the market.
10. Merck
Merck is a leading developer of oncology biosimilars, with a market share of 3%. The company’s biosimilars for bevacizumab and filgrastim are expected to drive growth in the coming years.
Insights:
The global oncology biosimilars market is poised for significant growth in the coming years, driven by the increasing demand for cost-effective cancer treatments. With the top 10 oncology biosimilars developers leading the way, we can expect to see a surge in the availability of biosimilars for a wide range of cancer therapies. By 2026, the market is projected to reach $12.8 billion, representing a lucrative opportunity for developers and healthcare providers alike. As more biosimilars enter the market, patients can benefit from increased access to affordable cancer treatments, ultimately improving outcomes and reducing healthcare costs.
Related Analysis: View Previous Industry Report
